A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma (Q33402531)

9 January 2018

title

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma (English)

1 reference

9 January 2018

main subject

phase II clinical trial

0 references

author name string

Edward Pan

1

1 reference

9 January 2018

Daohai Yu

2

1 reference

9 January 2018

Binglin Yue

3

1 reference

9 January 2018

Lisa Potthast

4

1 reference

9 January 2018

Sajeel Chowdhary

5

1 reference

9 January 2018

Pamela Smith

6

1 reference

9 January 2018

Marc Chamberlain

7

1 reference

9 January 2018

publication date

26 July 2012

1 reference

9 January 2018

Journal of Neuro-Oncology

published in

1 reference

9 January 2018

volume

110

1 reference

9 January 2018

issue

1

1 reference

9 January 2018

page(s)

111-118

1 reference

9 January 2018

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Optimal two-stage designs for phase II clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

14 July 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0943-Z

Brain metastasis in renal cell cancer responding to sunitinib.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5735835

10.1007/S11060-012-0943-Z

31 October 2018

Identifiers

DOI

1 reference

9 January 2018

Dimensions Publication ID

0 references

1 reference

9 January 2018

PubMed publication ID

22832897

1 reference

9 January 2018